Institute for OneWorld Health

From Wikipedia, the free encyclopedia

The Institute for OneWorld Health is a 501(c)(3) nonprofit pharmaceutical company founded in 2000 to develop safe, effective, and affordable new medicines for people with infectious diseases in the developing countries.

Drug development efforts

Currently, two drugs are under development a drug to treat Chagas disease in Latin America and a drug to cure visceral leishmaniasis in India. Paromomycin, the drug being developed to treat visceral leishmaniasis, was granted orphan drug status in 2005 by both the FDA and EMEA. (abstract preserved by National Health Service) Prior to this approval, Phase 3 clinical trials for this were conducted in India in 2003—2004. The overall conclusion was that and were similar to the comparison agent in the trials, amphotericin B, results which in August 2006 led to approval for treatment of visceral leishmaniasis by the Indian government.

Executives

  • Dr. Victoria Hale Ph.D., CEO and Chairman of the Board of Directors.
  • Dr. Ahvie Herskowitz M.D., COO and Chief Medical Officer.

    • Major supporters

  • Bill & Melinda Gates Foundation (the Institute received 96% of its funding from the Foundation as of 2006)
  • Amgen, Chiron Corporation, Gap, Lehman Brothers, Pfizer, Vital Spark Foundation, Skoll Foundation


    • Next Page


    This article is based on an article from Wikipedia, the free encyclopedia and is available under the terms of GNU Free Documentation License.
    In the Wikipedia there is a list with all authors of this article available.